Background COVID-19 may spread through various ways ranging from asymptomatic to
severe forms, until respiratory failure, critical conditions and death occurs. There is a …

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica
spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease …

Objective To identify risk factors for an increased lethality of COVID-19 in patients with
multiple sclerosis (MS). Methods We searched scientific databases to identify cohort studies …

Objectives To gather, synthesize, and meta-analyze data regarding the risk factors
associated with a severe course of COVID-19 among patients with multiple sclerosis …

Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …

Objective To estimate whether the risk of death from COVID-19 in patients with multiple
sclerosis (MS) exceeds that of the general population. Methods We conducted a pooled …

Disease modifying treatments (DMTs) should be regularly continued in relation to SARS-
CoV-2 vaccination, but an ad hoc timing is required with B-cell depleting agents. SARS-CoV …

There is growing concern that multiple sclerosis (MS) patients on certain therapies may be at
higher risk for severe coronavirus disease 2019 (COVID-19). We conducted a systematic …

Background and purpose Clinical outcomes of multiple sclerosis (MS) patients affected by
coronavirus disease 2019 (COVID‐19) have been thoroughly investigated, but a further …

Purpose The study was purposed to investigate the effect of COVID-19 disease on fatigue,
sleep quality, physical activity, quality of life, and psychological status in people with MS …